Combined treatment with (11) and (12) inhibits the proliferation of pancreatic cancer (Miapaca-2 and Panc-1 cells) by induction of caspase-3 cleavage, also acts by inhibition of migration of human pancreatic cancer cells, the phosphorylation of focal adhesion kinase (FAK), and p38 signaling [51]. Here, CASP3 is linked to pancreatic neoplasm.